Injections on posterior bladder wall excluding the trigone ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 226 | Interstitial cystitis with Hunners ulcer | 1 |
226. Interstitial cystitis with Hunners ulcer
Clinical trials : 143 / Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02297100 (ClinicalTrials.gov) | December 2014 | 30/9/2014 | Intravesicular Onabotulinumtoxin A in Interstitial Cystitis | The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4 | Interstitial Cystitis | Drug: Onabotulinumtoxin A;Procedure: injections upper aspect of trigone of urinary bladder;Procedure: injections on posterior bladder wall excluding the trigone | Wake Forest University Health Sciences | Allergan | Completed | 18 Years | 80 Years | Female | 27 | Phase 4 | United States |